Financial news app, Cms (00867) announced that the Hong Kong Special Administrative Region Government Pharmaceutical Business and Poison Management Bureau (PPBHK) has approved the application for listing the new drug phospholipid buti Ni cream on November 4, 2024, and received the drug/product registration certificate on November 5, 2024. The product is used to treat non-segmental vitiligo with facial involvement in adolescents and adults aged 12 and above.